Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
Iain C Macdougall, Claire White, Stefan D Anker...
https://pubmed.ncbi.nlm.nih.gov/30365356/Actively Recruiting
Led by Rigshospitalet, Denmark · Updated on 2026-05-29
74
Participants Needed
1
Research Sites
17 weeks
Total Duration
Researchers are evaluating adjunctive anemia treatment in patients with infective endocarditis IE, a serious bacterial infection of the heart valves and surrounding structures. IE is linked to high morbidity and mortality, and anemia is common in these patients due to infection, inflammation, and other health issues. This study aims to assess whether adding treatments like intravenous iron, erythropoietin, and vitamin supplementation can safely improve hemoglobin levels and physical function compared to standard care. Participants will be randomly assigned to receive either adjunctive anemia therapy or standard care. The anemia treatment combines a one-time intravenous infusion of Ferriderisomaltose, erythropoietin injections adjusted by hemoglobin levels, and dietary counseling including vitamins such as B12 and folic acid if needed. Treatment starts after clinical stabilization and continues with monitoring. The study includes a 3-month clinical follow-up and long-term monitoring through medical records and registries for up to 10 years. During the study, participants will undergo physical capacity testing using a standardized 6-minute walk test, quality of life questionnaires, and blood samples for various markers. Close safety monitoring will track infection status, hemoglobin levels, and any adverse events. The main outcome is physical capacity at six weeks post-randomization. Additional assessments at 3 months will evaluate hemoglobin changes, cardiac function, recurrent infections, stroke, mortality, and patient-reported quality of life, ensuring a comprehensive evaluation of treatment impact.
CONDITIONS
Anemia Therapy in Patients With Infective Endocarditis
N
Nareen S Nareen, MD
J
Julie G Hjulmand, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rigshospitalet, Denmark
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Treatment starts immediately after randomization and erythropoietin dosing is adjusted weekly; total treatment duration depends on hemoglobin response up to 3 months follow-up.
Participants receive adjunctive anemia therapy consisting of a one-time intravenous iron infusion, erythropoietin infusions up to three doses as needed, and vitamin supplementation alongside their existing treatment for infective endocarditis.
Weekly visits for hemoglobin monitoring and treatment adjustments during initial weeks; 1 baseline visit and 1 follow-up visit at 3 months
Duration - 3 months active clinical follow-up with additional 10 years long-term monitoring
Participants are monitored for clinical outcomes including physical capacity, hemoglobin levels, quality of life, infection recurrence, and adverse events for 3 months after treatment initiation, with long-term follow-up through medical records and registries up to 10 years.
Visits at 6 weeks and 3 months after randomization including physical tests and blood sampling
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Iain C Macdougall, Claire White, Stefan D Anker...
https://pubmed.ncbi.nlm.nih.gov/30365356/Tomas Ganz
https://pubmed.ncbi.nlm.nih.gov/31532961/Jing Tan, Jing Wei
https://pubmed.ncbi.nlm.nih.gov/22648095/Akshay A Shah, Killian Donovan, Claire Seeley...
https://pubmed.ncbi.nlm.nih.gov/34767026/Ugo Salvadori, Fabio Vittadello, Ahmad Al-Khaffaf...
https://pubmed.ncbi.nlm.nih.gov/31855154/Toros Kapoian, Neeta B O'Mara, Ajay K Singh...
https://pubmed.ncbi.nlm.nih.gov/18216316/Mette M Berger, Alan Shenkin, Anna Schweinlin...
https://pubmed.ncbi.nlm.nih.gov/35365361/M Alan Brookhart, Janet K Freburger, Alan R Ellis...
https://pubmed.ncbi.nlm.nih.gov/23787911/Michael J Shoemaker, Amy B Curtis, Eric Vangsnes...
https://pubmed.ncbi.nlm.nih.gov/23997688/Purnima Erichsen, Gunnar H Gislason, Niels Eske Bruun
https://pubmed.ncbi.nlm.nih.gov/27339641/Rigshospitalet, Denmark
Lead Sponsor